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Selective targeting of IRF4 by synthetic microRNA-125b-5p
mimics induces anti-multiple myeloma activity in vitro and
in vivo
E Morelli1, E Leone1, ME Gallo Cantaﬁo1, MT Di Martino1, N Amodio1, L Biamonte1, A Gullà1, U Foresta1, MR Pitari1, C Botta1, M Rossi1,
A Neri2, NC Munshi3,4, KC Anderson3, P Tagliaferri1 and P Tassone1,5
Interferon regulatory factor 4 (IRF4) is an attractive therapeutic target in multiple myeloma (MM). We here report that expression of
IRF4 mRNA inversely correlates with microRNA (miR)-125b in MM patients. Moreover, we provide evidence that miR-125b is
downregulated in TC2/3 molecular MM subgroups and in established cell lines. Importantly, constitutive expression of miR-125b-5p
by lentiviral vectors or transfection with synthetic mimics impaired growth and survival of MM cells and overcame the protective
role of bone marrow stromal cells in vitro. Apoptotic and autophagy-associated cell death were triggered in MM cells on miR-125b-5p
ectopic expression. Importantly, we found that the anti-MM activity of miR-125b-5p was mediated via direct downregulation of IRF4
and its downstream effector BLIMP-1. Moreover, inhibition of IRF4 translated into downregulation of c-Myc, caspase-10 and cFlip,
relevant IRF4-downstream effectors. Finally, in vivo intra-tumor or systemic delivery of formulated miR-125b-5p mimics against
human MM xenografts in severe combined immunodeﬁcient/non-obese diabetic mice induced signiﬁcant anti-tumor activity and
prolonged survival. Taken together, our ﬁndings provide evidence that miR-125b, differently from other hematologic malignancies,
has tumor-suppressor activity in MM. Furthermore, our data provide proof-of-concept that synthetic miR-125b-5p mimics are
promising anti-MM agents to be validated in early clinical trials.
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INTRODUCTION
Multiple myeloma (MM) is a genetically complex malignancy from
the outset, with progressive acquisition of genetic lesions
mediating drug resistance and high disease burden.1 Despite
recent progress in the understanding MM pathobiology and the
availability of innovative drugs which have improved clinical
outcome, the disease eventually progresses to a drug-resistant
lethal stage (plasma cell leukemia)2–4 and novel therapeutic
strategies are therefore eagerly awaited. Indeed, one of the major
challenges in treating MM is its genomic and phenotypic
heterogeneity.5 Hence, an optimal therapy would target an
essential regulatory pathway shared by all disease subsets.6
Interferon regulatory factor 4 (IRF4) is a lymphocyte-speciﬁc
transcription factor.7 Interference with IRF4 expression is lethal for
MM cells, irrespective of their genetics, making IRF4 an ‘Achilles’
heel’ that may be exploited therapeutically.8 Speciﬁcally, IRF4 is
oncogenic and overexpressed when translocated to actively
transcribed genomic regions in some MM patients, but it also
has a survival effect in MM cells in the absence of translocations or
overexpression.7,8 A relevant IRF4 target gene is c-Myc,7,8 which
has a prominent role in the pathogenesis of MM.7,8 Another
downstream IRF4 effector is B-lymphocyte-induced maturation
protein-1 (BLIMP-1):9 indeed, knockdown of BLIMP-1 causes
apoptosis in MM cells. These ﬁndings suggest that IRF4 may
regulate MM cell survival through modulation of BLIMP-1.9
Moreover, it has been recently demonstrated that caspase-10
(casp-10) and cFlip genes are transactivated by IRF4: importantly,
the evidence that all MM cell lines require casp-10 and cFLIP for
survival led to the hypothesis that loss of the proteolytic activity of
the casp-10/cFlip heterodimer mediates MM cell death induced by
IRF4 knockdown.10 All these data indicate IRF4 as an attractive
therapeutic target in MM. However, efﬁcient in vivo strategies
aimed at blocking IRF4 pathway are still lacking.
MicroRNAs (miRNAs) are small non-coding RNAs of 19–25
nucleotides, which regulate gene expression by degrading or
inhibiting translation of target mRNAs, primarily via base pairing
to partially or fully complementary sites in the 3ʹ untranslated
region (UTR).11 Targeting deregulated miRNAs in cancer cells is
emerging as a novel promising therapeutic approach,12–14
including in MM.15–34 In this scenario, replacement of tumor-
suppressor miRNAs by synthetic oligonucleotides (miRNA mimics)
offers a new therapeutic opportunity to restore a loss-of-function
in cancer, that has been an unmet need for drug developers.35
Here, we show that IRF4 expression is regulated by
microRNA-125b-5p (miR-125b-5p) in patient-derived MM cells
and MM cell lines. In most of these cells, enforced expression of
miR-125b-5p affects growth and survival, acting via IRF4 down-
regulation and impairment of its downstream signaling. Overall,
our ﬁndings demonstrate that miR-125b is a tumor suppressor in
MM, and provide the rationale for development of miR-125b-5p
mimics as novel therapeutics.
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MATERIALS AND METHODS
MM patient cells and cell lines
Following the Magna Graecia University IRB study approval, primary MM
cells were isolated from bone marrow (BM) aspirates, as described,19 from
24 newly diagnosed MM patients who had provided the informed consent.
For transfection purposes and proliferation/survival assays, peripheral
blood mononuclear cells (PBMCs) from healthy donors have been used as
controls. MM cell lines were cultured as described.19 HS-5 human stromal
cell line (purchased from ATCC, Manassas, VA, USA, CRL-11882) was
cultured in Dulbecco's Modiﬁed Eagle Medium supplemented with 10%
fetal bovine serum and 1% penicillin/streptomycin (see Supplementary
Methods for detailed information).
Virus generation and infection of cells
Cells stably expressing green ﬂuorescent protein transgene were obtained
as described.21 To generate cells stably expressing luciferase transgene,
NCI-H929 cells were transduced with pLenti-III-PGK-Luc (ABM Inc.,
Richmond, BC, Canada) vector. MM cells stably expressing miR-125b-1
and miR-125b-2 genes were transduced with Lenti-miR-125b-1 and Lenti-
miR-125b-2 miRNA precursor constructs (System Biosciences, CA, USA);
lentiviral particles were produced and transduced as previously
described.19
RNA extraction and qRT-PCR.
RNA samples of healthy donors BM-derived plasma cells were purchased
(AllCells LLC, Alameda, CA, USA). Total RNA extraction from MM cells
and quantitative real-time PCR were performed as previously
described (see Supplementary Methods for detailed information).19
In vitro transfection of MM cells
Synthetic miRNA mimics were purchased from Ambion (Applied Biosys-
tems, Carlsbad, CA, USA), while synthetic miRNA inhibitors were purchased
from Exiqon (Vedbaek, Rudersdal, Denmark). Silencer Select siRNAs were
purchased from Ambion (Applied Biosystems). All the oligos were used at
100 nmol/l ﬁnal concentration. A total of 2,5 × 105 cells were transfected
using Neon Transfection System (Invitrogen, Carlsbad, CA, USA) (2 pulse at
1.050 V, 30 ms) and the transfection efﬁciency, evaluated by ﬂow-
cytometric analysis relative to a FAM dye-labeled miRNA inhibitor negative
control, reached 85 to 90%. The same conditions were applied for
transfection of MM cells with 5 μg of expression vectors carrying the open
reading frames (ORFs) of BLIMP-1 (EX-Z5827-M11), IRF4 (EX-M0891-M11) or
empty vector (EX-EGFP-M11) (GeneCopeia, Rockville, MD, USA).
Survival assay
Cell viabilty was evaluated by Cell Counting Kit-8 (CCK-8) assay (Dojindo
Molecular Technologies, Mashikimachi, Japan) and 7-Aminoactinomycin (7-
AAD) ﬂow cytometry assay (BD Biosciences, San Jose, CA, USA), according
to manufacturer’s instructions.
Detection of apoptosis
Apoptosis was investigated by three different assays: Annexin V/7-AAD ﬂow
cytometry assay, terminal-deoxynucleotidyl transferase-dUTP nick end
labeling (TUNEL) assay and western blot analysis of caspases expression
and cleavage. To perform TUNEL assay, transfected cells were ﬁxed using 4%
paraformaldehyde and then permeabilized using 0.25% Triton X-100,
according to manufacturer’s instructions. Cells were stained with a TUNEL
assay (Click-iT TUNEL Alexa Fluor 594 Imaging Assay, Invitrogen, 10246) to
identify those with fragmented DNA. Nuclei were counterstained with
Hoechst 33342 (Life Technologies, CA, USA). Image acquisition was done
using EVOS FLOID (Life Technologies) equipped with a 20× Nikon objective.
Western blot analysis
Whole cell protein extracts were prepared from MM cell lines and from
PBMCs in NP40 CellLysis Buffer (Life Technologies) containing a cocktail of
protease inhibitors (Sigma, Steinheim, Germany). Cell lysates were loaded
and polyacrylamide gel electrophoresis separated. Proteins were transferred
by Trans-Blot Turbo Transfer Starter System (Bio-Rad, Hercules, CA, USA) for
7min. After protein transfer, the membranes were blotted with the primary
antibodies (see Supplementary methods for detailed information).
Animals and in vivo model of human MM
Male CB-17 Severe Combined Immunodeﬁcient (SCID) mice (6–8 weeks old;
Harlan Laboratories, Inc., Indianapolis, IN, USA) were housed and monitored
in our Animal Research Facility. Experimental procedures and protocols had
been approved by the Magna Graecia University IRB and conducted
according to protocols approved by the National Directorate of Veterinary
Services (Italy, Rome). Mice were s.c. inoculated with 5×106 NCI-H929 cells
and treatment started when palpable tumors became detectable. Sample
size (that is, number of animals to be inoculated with MM cells) was chosen
accordingly to our experience.16–20 Tumor sizes were measured as
described,19 and the investigator was blinded to group allocation. Tumor
size of luciferase gene-marked NCI-H929 xenografts was also measured by
IVIS Lumina II (PerkinElmer, Waltham, MA, USA). Oligos were NLE-formulated
within MaxSuppressor In Vivo LANCEr II (BIIo Scientiﬁc, Austin, TX, USA) to
achieve an efﬁcient delivery, as reported.16,27
Statistical analysis
Each experiment was performed at least three times and values are reported
as mean± s.d. Comparisons between groups were made with student’s t-
test, while statistical signiﬁcance of differences among multiple groups was
determined by GraphPad software (www.graphpad.com). Graphs were
obtained using Graphpad Prism version 6.0 (GraphPad Software, La Jolla, CA,
USA). P-value o0.05 was accepted as statistically signiﬁcant.
RESULTS
Inverse correlation between IRF4 mRNA and miR-125b in MM
patients
To identify IRF4-targeting miRNAs, we interrogated microRNA
Data Integration Portal (mirDIP), applying the high precision quality
Table 1. In silico search for IRF4-targeting miRNAs
Gene MicroRNA Source Score (s.d.)
IRF4 hsa-mir-125a-5p picTar_ver2_hg18_Mar2006_mammals 4.52261
IRF4 hsa-mir-125b-5p picTar_ver2_hg18_Mar2006_mammals 5.02513
IRF4 hsa-mir-128 picTar_ver2_hg18_Mar2006_mammals 3.51759
IRF4 hsa-mir-27a-3p picTar_ver2_hg18_Mar2006_mammals 5.02513
IRF4 hsa-mir-27b-3p picTar_ver2_hg18_Mar2006_mammals 6.03015
IRF4 hsa-mir-30a-5p picTar_ver2_hg18_Mar2006_mammals 2.01005
IRF4 hsa-mir-30b-5p picTar_ver2_hg18_Mar2006_mammals 1.00503
IRF4 hsa-mir-30c-2 picTar_ver2_hg18_Mar2006_mammals 1.00503
IRF4 hsa-mir-30d-5p picTar_ver2_hg18_Mar2006_mammals 2.51256
IRF4 hsa-mir-30e-5p picTar_ver2_hg18_Mar2006_mammals 4.52261
IRF4 hsa-mir-4319 picTar_ver2_hg18_Mar2006_mammals 14.5729
IRF4 hsa-mir-513a-5p picTar_ver2_hg18_Mar2006_mammals 14.0704
Abbreviations: IRF4, interferon regulatory factor; miRNA, microRNA.
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ﬁlter.36 As shown in Table 1, this analysis disclosed 12 mature
miRNAs including miR-125a-5p, miR-125b-5p, miR-128, miR-27a-
3p, miR-27b-3p, miR-30a-5p, miR-30b-5p, miR-30c-2, miR-30d-5p,
miR-30e-5p, miR-4319 and miR-513a-5p. We next attempted to
correlate the expression of these miRNAs and IRF4 mRNA in our
dataset (55 MM and 21 plasma cell leukemia patients)(GSE39925).
This integrated approach revealed a signiﬁcant inverse correlation
between IRF4 mRNA and ﬁve precursor-miRNAs (pre-miR-125b-1,
pre-miR-125b-2, pre-miR-30b, pre-miR-30c-2 and pre-miR-30d)
among all MM and plasma cell leukemia patients examined
(Figures 1a and b and Supplementary Fig. S1A). Importantly, when
a second dataset (GSE47552) was interrogated, the inverse
correlation with IRF4 mRNA was conﬁrmed only for pre-
miR-125b-1 (Supplementary Fig. S1B), strengthening a possible
role of miR-125b-5p as IRF4 negative regulator in MM patients.
By qRT-PCR, we then evaluated the expression of miR-125b-5p in
24 CD138+ primary patient MM (ppMM) cells, 10 MM cell lines and
3 samples of CD138+ BM-derived plasma cells from healthy donors
(HD-PCs). A signiﬁcant downregulation of miR-125b-5p was found
in MM cell lines (Figure 1c, with single values plotted in
Supplementary Fig. S2), while the downregulatory trend observed
in ppMM cells reached statistical signiﬁcance within the TC2 and
TC3 subgroups only (Figures 1c and d).
Enforced expression of miR-125b impairs growth and survival of
MM cells
To evaluate the effects induced by miR-125b, we transduced 3 MM
cell lines (NCI-H929, SK-MM-1, RPMI-8226) with lentiviral vectors
carrying either miR-125b-1 or miR-125b-2 (Lenti-miR-125b-1 or
Lenti-miR-125b-2) genes. The effects on cell proliferation were
assessed by CCK-8 assay at 2, 3 and 4 days after selection by
puromycin. As shown in Figures 2a and b, constitutive expression
of either Lenti-miR-125b-1 or Lenti-miR-125b-2 resulted in a strong
inhibition of cell growth. Next, we transfected MM cell lines with
either synthetic miR-125b-5p mimics or inhibitors. We found that
ectopic expression of miR-125b-5p inhibitors did not affect the
proliferation of MM cells (Figures 2c and d); conversely, transfec-
tion of miR-125b-5p mimics strongly impaired growth and survival
of most MM cell lines (9 out of 10) (Figures 2e and f). Importantly,
miR-125b-5p mimics reduced the viability of ppMM cells from 3
individuals (Figure 2g), but not of PBMCs from 6 healthy donors
(Figure 2h). Taken together, these results indicate that enforced
expression of miR-125b-5p inhibits growth and survival of MM
cells, consistent with a tumor-suppressor function of this miRNA.
Notably, baseline expression of miR-125b-5p did not correlate
with the sensitivity/response to synthetic mimics or inhibitors,
suggesting that miR-125b-5p expression is not predictive of
in vitro anti-MM activity. Furthermore, miR-125b-5p mimics were
lethal to MM cells irrespective of their genetics.
miR-125b-5p mimics inhibit proliferation of MM cells via targeting
IRF4
To investigate whether IRF4 expression could be affected by
ectopic miR-125b-5p, both qRT-PCR and western blot analysis
were performed in 3 MM cell lines transfected with miR-125b-5p
mimics or scrambled controls (miR-NC). Speciﬁcally, the IRF4
translocated SK-MM-1, along with NCI-H929 and RPMI-8226 cells
(not IRF4 translocated), were selected for this analysis. As shown in
Figures 3a and b, transfection of miR-125b-5p downregulated IRF4
at both mRNA and protein levels in all MM cell lines. Notably, the
only MM cell line resistant to miR-125b-5p overexpression
lacked detectable IRF4 (i.e. RPMI-8226/Dox40 cells, which were
Figure 1. miR-125b inversely correlates with IRF4 mRNA in MM patients. Analysis of IRF4 mRNA and either (a) miR-125b-1 or (b) miR-125b-2
expression levels in patient's multiple myeloma cells from published data set GSE39925. (c) qRT-PCR analysis of miR-125b-5p expression using
total RNA from 24 primary patient MM cells, 10 MM cell lines and 3 samples of bone marrow-derived plasma cells from healthy donors (HD
PCs). (d) MMs were TC classiﬁed according to the presence of recurrent IGH chromosomal translocations and Cyclin D expression as previously
described,19 and miR-125b-5p expression in TC2 and TC3 subgroups is plotted. Raw Ct values were normalized to RNU44 housekeeping
snoRNA and expressed as 2−ΔCt values. Values represent mean± s.e. of three different experiments.
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generated from the parental RPMI-8226 by continuous exposure
to increasing amounts of doxorubicin to culture medium, is
characterized by loss of miR-125b-5p relevant targets)
(Supplementary Fig. S3A). Consistently, we found that viability of
RPMI-8226/Dox40 cells was not affected by IRF4 siRNA silencing
(Supplementary Fig. S3B); in contrast, siRNA-transfection of both
NCI-H929 and SK-MM-1 cells conﬁrmed its role in supporting their
survival (Supplementary Fig. S3B). We next investigated whether
ectopic expression of a cDNA containing only the coding region of
IRF4 and lacking the miR-125b-5p-targeted 3ʹ UTR could protect
MM cells from miR-125b-5p anti-proliferative effects. As shown in
Figure 3c, transfection of IRF4 construct increased IRF4 protein
expression which was not affected by miR-125b-5p mimics.
Importantly, IRF4 overexpression rescued SK-MM-1 cells from the
miR-125b-5p exerts anti-myeloma activity
E Morelli et al
2176
Leukemia (2015) 2173 – 2183 © 2015 Macmillan Publishers Limited
growth-inhibitory activity of either IRF4 siRNAs (Supplementary
Fig. S3C) or miR-125b-5p mimics (Figure 3d), indicating that
miR-125b-5p exerts its anti-MM activity via targeting IRF4.
Enforced expression of miR-125b-5p impairs IRF4 signaling in MM
cell lines
We next investigated the effects of miR-125b-5p on the molecular
network underlying IRF4 activity in MM. Interestingly, the IRF4-
downstream effector BLIMP-1 has been proven to be a direct
target of miR-125b-5p.37 As shown in Figure 4a and
Supplementary Fig. S4A, transfection of miR-125b-5p mimics
downregulated BLIMP-1 protein in SK-MM-1 and NCI-H929 cells.
Thus, we investigated whether ectopic expression of a cDNA
containing only the coding region of BLIMP-1 and lacking the
miR-125b-5p-targeted 3ʹ UTR could protect MM cells from
miR-125b-5p effects. Importantly, co-transfection with BLIMP-1
construct weakened the anti-proliferative effect of miR-125b-5p
mimics as well of BLIMP-1 siRNAs (Figure 4c and Supplementary
Fig. S4B), indicating that also BLIMP-1 mediates the anti-MM
activity of miR-125b-5p. Of note, miR-125b-5p-induced down-
regulation of BLIMP-1 was not abrogated in SK-MM-1 cells
co-transfected with the coding region of IRF4 (Figure 4b),
consistent with the notion that BLIMP-1 is a direct target of
miR-125b-5p which circumvents IRF4 activity on BLIMP-1. Other
IRF4-downstream effectors, with a prominent role in MM
pathogenesis, are c-Myc, casp-10 and cFLIP.8,10 By western blot
analysis, we found reduced expression of these proteins in
SK-MM-1 (Figure 4d) and NCI-H929 (Supplementary Fig. S4E) cells
at 24–48 h after transfection with miR-125b-5p. Expression of both
casp-10 and cFlip was also reduced at mRNA levels
(Supplementary Fig. S4F) by miR-125b-5p mimics. In silico search
for target prediction identiﬁed both casp-10 and cFlip as bona ﬁde
direct targets for miR-125b-5p. To validate this interaction in MM
cells, SK-MM-1 cells were co-transfected with miR-125b-5p mimics
or scrambled oligonucleotides, together with an expression vector
carrying the 3ʹ UTR of casp-10 or cFlip mRNA cloned downstream of
luciferase reporter gene. Of note, we did not ﬁnd signiﬁcant
changes in 3ʹ UTR luciferase activity after miR-125b-5p over-
expression, ruling out direct targeting of casp-10 and cFlip mRNAs
by miR-125b-5p (Supplementary Fig. S4G). Moreover, miR-125b-5p-
induced downregulation of c-Myc, casp-10 and cFlip was abrogated
in SK-MM-1 cells co-transfected with the coding region of IRF4
(Figure 4e), indicating that miR-125b-5p-induced downregulation of
casp-10, c-Myc and cFlip occurs via IRF4 inhibition. Taken together,
our ﬁndings demonstrate that miR-125b-5p mimics impair IRF4
signaling in MM cells (Figure 4f). We also found that direct targeting
Figure 3. IRF4 downregulation mediates miR-125b-5p anti-MM activity. (a) qRT-PCR analysis of IRF4 expression in SK-MM-1, NCI-H929 and
RPMI-8226 cells 48 h after transfection with miR-125b-5p or miR-NC. The results shown are average mRNA expression levels after
normalization with GAPDH and ΔΔCt calculations. (b) Western blot analysis of IRF4 in SK-MM-1, NCI-H929 and RPMI-8226 cells transfected
with miR-125b-5p or miR-NC. Analysis was performed 24 and 48 h after cell transfection. γ-Tubulin was used as protein loading control.
(c) Western blot analysis of IRF4 in lysates from SK-MM-1 cells co-transfected with either IRF4 ORF expression vector or an empty vector and
miR-125b-5p or miR-NC (48-h time point). (d) CCK-8 assay of SK-MM-1 cells co-transfected with either IRF4 ORF expression vector or an empty
vector and miR-125b-5p or miR-NC (72-h time point). Data represent the average ± s.d. of three independent experiments.
Figure 2. Anti-proliferative effects of miR-125b in MM cells. (a) qRT-PCR analysis of miR-125b-5p expression in SK-MM-1 cells transduced with
either Lenti-miR-125b-1 or Lenti-miR-125b-2; the results are shown as average miR-125b-5p expression levels after normalization with RNU44
and ΔΔCt calculations. (b) CCK-8 proliferation assay of NCI-H929, SK-MM-1 and RPMI-8226 cells transduced with a lentivirus carrying either the
miR-125b-1 (Lenti-miR-125b-1) or the miR-125b-2 (Lenti-miR-125b-2) genes; the effects on cell proliferation were assessed at 2, 3 and 4 days
after selection by puromycin. qRT-PCR analysis of miR-125b-5p expression in SK-MM-1 cells transfected with either (c) miR-125b-5p inhibitors
or (e) miR-125b-5p mimics; the results are shown as average miR-125b-5p expression levels after normalization with RNU44 and ΔΔCt
calculations. (d) CCK-8 proliferation assay was performed 2–4 days after transfection of eight MM cell lines (MM.1S, MM.1R, U266/LR7,
RPMI-8226, RPMI-8226/DOX40, SK-MM-1, KMS-12-BM and INA-6) with miR-125b-5p inhibitors or scrambled controls (miR-NC inhibitors).
(f) CCK-8 proliferation assay was performed 2–4 days after transfection of 10 MM cell lines (NCI-H929, U266, MM.1S, MM.1R, U266/LR7,
RPMI-8226, RPMI-8226/DOX40, SK-MM-1, KMS-12-BM and INA-6) with miR-125b-5p mimics or scrambled controls (miR-NC mimics). (g) CCK-8
assay of CD138+ cells from three different MM patients transfected with miR-125b-5p or miR-NC. The assay was performed 48 h after cell
transfection. (h) 7-AAD ﬂow cytometry assay was performed 48 h after transfection of PBMCs from six healthy donors (HDs) with miR-125b-5p
or miR-NC. Data represent the average ± s.d. of three independent experiments. P-values were obtained using two-tailed t-test.
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of IRF4 or BLIMP-1 and indirect modulation of c-Myc, casp-10 and
cFlip mediates anti-MM activity of this miRNA.
miR-125b-5p mimics trigger both apoptotic and autophagy-
associated cell death
Inhibition of IRF4, as well of BLIMP-1 or c-Myc, has been mainly
related to induction of apoptosis,9,38 while targeting casp-10 or its
interaction with cFlip triggers autophagic cell death of MM cells.10
On this basis, we next determined whether apoptotic or
autophagy-associated cell death occurred in MM cells with
enforced expression of miR-125b-5p. Using Annexin V/7-AAD ﬂow
cytometry assay, we found that miR-125b-5p mimics triggered
exposure of phosphatidylserine (PS) and phosphatidylethanola-
mine (PE) on the cell surface of SK-MM-1 (Figure 5a), NCI-H929 and
U266 cells (Supplementary Fig. S5A), followed by cell membrane
disruption. Moreover, by TUNEL assay and western blotting, we
found that miR-125b-5p induced DNA-fragmentation (Supplementary
Fig. S5B) and cleavage/activation of both initiator casp-8 and
effector casp-3 (Figure 5b and Supplementary Fig. S5C) in MM
cells. Of note, apoptosis was not detected when miR-125b-5p-
transfected cells were treated with the pan-caspase inhibitor
Z-VAD-fmk (Figure 5c). Overall, these results indicate that
miR-125b-5p is pro-apoptotic in MM cells. Moreover, by ﬂow
cytometry analysis of Cyto-ID stained cells, we observed an
increase of autophagic vacuoles in SK-MM-1, XG-1 and INA-6 cells,
at 48 h after transfection with miR-125b-5p (Figure 5d). Impor-
tantly, the increase of autophagic vacuoles occurred to a similar
extent in cells transfected with miR-125b-5p compared with cells
starved for 48 h. Moreover, western blot analysis showed
decreased p-62/SQSTM1 and increased Beclin-1 and proteolytic
active LCIIIB (Figure 5e), further indicating that miR-125b-5p-
induced cell death can be associated with autophagy induction in
MM cells. Indeed, exposure of miR-125b-5p-transfected cells to
autophagy inhibitor cloroquine resulted in increased cell death
(Figure 5f), thus suggesting a protective role of autophagy in our
experimental settings.
miR-125b-5p mimics antagonize the BMSCs protective role on MM
cells
BMmilieu strongly supports survival and proliferation of MM cells.3
In this regard, we found that exogenous interleukin-6 (IL-6) or
insulin-like growth-factor-1 (IGF-1) or hepatocyte growth-factor
(HGF) signiﬁcantly reduced miR-125b-5p expression in all MM cell
lines except U266 cells (Figure 6a), which express L-Myc instead of
Figure 4. Impairment of IRF4 signaling by miR-125b-5p. (a) Western blot analysis of BLIMP-1 in SK-MM-1 cells transfected with miR-125b-5p or miR-
NC. Analysis was performed 24 and 48 h after cell transfection. γ-Tubulin was used as protein loading control. (b) Western blot analysis of BLIMP-1
in lysates from SK-MM-1 cells co-transfected with either BLIMP-1 ORF expression vector or IRF4 ORF expression vector or an empty vector and
miR-125b-5p or miR-NC (48-h time point). (c) CCK-8 assay of SK-MM-1 cells co-transfected with either BLIMP-1 ORF expression vector or an empty
vector and miR-125b-5p or miR-NC (72-h time point). (d) Western blot analysis of c-Myc, Casp-10 and cFLIP in SK-MM-1 cells transfected with
miR-125b-5p or miR-NC. Analysis was performed 24 and 48 h after cell transfection. GAPDH or γ-Tubulin were used as protein loading controls. (e)
Western blot analysis of c-Myc, Casp-10 and cFLIP in lysates from SK-MM-1 cells co-transfected with either IRF4 ORF expression vector or an empty
vector and miR-125b-5p or miR-NC (48-h time point). GAPDH was used as protein loading control. All the experiments were performed in
triplicate. Representative pictures are shown. (f) Explanatory cartoon of miR-125b-5p-mediated impairment of IRF4 signaling.
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c-Myc. Since c-Myc suppresses miR-125b transcription39,40 and is
upregulated by IL-6, IGF-1 and HGF,40–42 we investigated whether
these factors downregulate miR-125b in MM cells through c-Myc
induction. Speciﬁcally, we treated c-Myc-expressing SK-MM-1 and
c-Myc-defective U266 cells with the 10058-F4 small molecule
inhibitor of Myc–Max heterodimerization38 and with the JQ1 BET-
bromodomain inhibitor, which is reported to inhibit c-Myc
transcription.43 Importantly, both compounds triggered a signiﬁcant
miR-125b-5p upregulation in SK-MM-1 cells, but not in U226 cells
(Figure 6b), indicating that c-Myc-independent downregulation
of miR-125b occurs in this cell line. Moreover, IL-6 or IGF-1 or HGF
did not affect miR-125b-5p expression in SK-MM-1 cells in the
presence of c-Myc inhibitors, indicating a c-Myc-mediated down-
regulation of miR-125b by exogenous addition of microenvironmental
growth factors (Figure 6c). Finally, we demonstrated that the anti-MM
activity of miR-125b-5p mimics was not antagonized by exogenous
growth promoting/pro-survival stimuli including IL-6, IGF-1 and HGF,
or by adherence of MM cell lines to HS-5 human stromal cells
(Figures 6d and e). This could be partly due to downregulation of
IL-6R/CD126 on the surface of MM cells. Indeed, by ﬂow cytometry
analysis, we did observe decreased expression of cell surface IL-6R/
CD126, also a further validated target of miR-125b-5p44 (Figure 6f),
which translated in reduced levels of phosphorylated/active STAT3
(pSTAT3-Y705) in IL-6-dependent INA-6 cells (Figure 6g).
In vivo delivery of NLE-formulated synthetic miR-125b-5p mimics
exerts anti-MM activity
In vivo anti-MM activity of miR-125b-5p was next evaluated in
Non-Obese Diabetic (NOD)/SCID mice bearing subcutaneous NCI-
H929 xenografts. In our ﬁrst model, luciferase gene-marked NCI-
H929 xenografts were intra-tumorally treated every other day with
1 mg/kg of oligos for a total of six injections. As shown in
Figures 7a–c, treatment resulted in a signiﬁcant tumor-growth
inhibition and prolonged survival. In a second model, treatments
were administered by i.p. injections of formulated oligos (twice
weekly, 1 mg/kg). In this model, we also observed anti-tumor
activity of miR-125b-5p, evidenced by growth inhibition and
prolonged survival (Figures 7d and e). Importantly, we found
increased miR-125b-5p in tumors retrieved from animals 48 h after
treatment, conﬁrming efﬁcient tumor cells uptake of formulated
oligos (Figure 7f). Consistent with our in vitro data, IRF4 signaling
Figure 5. miR-125b-5p increases both apoptosis and autophagic efﬂux in MM cells. (a) Annexin V/7-AAD staining of SK-MM-1 cells
transfected with miR-125b-5p or miR-NC. Flow cytometry analysis was performed 48–72 h after transfection. (b) Western blot analysis of
casp-3 and casp-8 activities in SK-MM-1 cells transfected with miR-125b-5p mimics or miR-NC. Analysis was performed 24–48 h after cell
transfection. γ-Tubulin or GAPDH were used as protein loading controls. (c) Annexin V/7-AAD staining of SK-MM-1 cells transfected
with miR-125b-5p or miR-NC. Six hours after electroporation either DMSO or zVAD-fmk were added to culture medium, at ﬁnal concentration
of 25 μM. Flow cytometry analysis was performed 48 h after transfection. (d) Cyto-ID uptake ﬂow cytometry assay was performed in seven
MM cell lines (NCI-H929, SK-MM-1, MM.1S, U266, RPMI-8226, XG-1 and INA-6) 48 h after transfection with miR-125b-5p or miR-NC. (e) Western
blot analysis of LC3B, Beclin-1 and p-62 was performed in XG-1 and SK-MM-1 cells transfected with miR-125b-5p or miR-NC. Analysis of
LC3B and Beclin-1 was performed 24 h after cell transfection, while analysis of p-62 was performed 48 h after cell transfection. GAPDH was
used as a protein loading control. (f) Annexin V/7-AAD staining of SK-MM-1 cells transfected with miR-125b-5p or miR-NC and then
exposed to increasing concentrations (0, 5, 10 and 20 μM) of the autophagy inhibitor cloroquine (added to culture medium 6 h after
electroporation). Flow cytometry analysis was performed 72 h after transfection. All the experiments were performed in triplicate.
Representative pictures are shown.
miR-125b-5p exerts anti-myeloma activity
E Morelli et al
2179
© 2015 Macmillan Publishers Limited Leukemia (2015) 2173 – 2183
was correlated with miR-125b-5p activity in vivo: downregulation
of IRF4 and BLIMP-1 (Figure 7g), along with decreased expression
of c-Myc, casp-10 and cFlip proteins (Figure 7h), was detected in
tumors retrieved from miR-125b-5p-treated animals. Overall, these
data indicate that in vivo anti-MM activity of miR-125b-5p mimics
is associated with abrogation of IRF4 signaling within MM
xenografts.
DISCUSSION
In this study, we investigated the anti-MM activity of the IRF4-
targeting miR-125b-5p. IRF4 is in fact an ‘Achilles’ heel’ for MM
cells and, therefore, represents an attractive therapeutic target in
this malignancy.7 miRNAs are natural antisense interactors of
mRNAs, and the availability of suitable in vivo delivery systems has
recently allowed the development of synthetic miRNA mimics in
early clinical trials. By querying mirDIP36 and applying the high
precision quality ﬁlter, we found 12 mature miRNAs predicted to
target the 3ʹ UTR of IRF4 mRNA, including miR-125b-5p.
Importantly, integrated analysis of miRNAs and mRNAs expression
proﬁles showed that miR-125b, but not the other predicted
miRNAs, inversely correlated with IRF4 mRNA in two different MM
datasets, strengthening the relevance of miR-125b as IRF4
negative regulator in MM patients. Furthermore, miR-125b-5p
was found signiﬁcantly downregulated in patients belonging to
TC2 and TC3 molecular subgroups, as well as in MM cell lines.
Altogether, these ﬁndings prompted us to investigate the role of
this miRNA in MM.
miR-125b is one of the most evolutionary conserved miRNAs.45
In humans there are two paralogs (hsa-miR-125b-1 on
Figure 6. miR-125b-5p antagonizes pro-survival effect of BM milieu. (a) Quantitative RT-PCR of miR-125b-5p expression in NCI-H929, KMS-12-
BM, INA-6, SK-MM-1 and U266 cells cultured in the presence or absence of either IL-6 (2.5 ng/ml) or IGF-1 (100 μg/ml) or HGF (150 μg/ml) (48-h
time point). Raw Ct values were normalized to RNU44 housekeeping snoRNA and expressed as ΔΔCt values calculated using the comparative
cross threshold method. miR-125b-5p expression levels in cells cultured in the absence of growth factors were set as an internal reference.
(b) Quantitative RT-PCR of miR-125b-5p expression in SK-MM-1 and U266 cells exposed to either DMSO or JQ1 (1 μM) or 10058-F4 (100 μM)
(48-h time point). Raw Ct values were normalized to RNU44 housekeeping snoRNA and expressed as ΔΔCt values calculated using the
comparative cross threshold method. miR-125b-5p expression levels in cells exposed to DMSO were set as an internal reference.
(c) Quantitative RT-PCR of miR-125b-5p expression in SK-MM-1 cells cultured in the presence or absence of either IL-6 (2.5 ng/ml) or IGF-1
(100 μg/ml) or HGF (150 μg/ml) and exposed to either DMSO or JQ1 (1 μM) or 10058-F4 (100 μM) (48-h time point). Raw Ct values were
normalized to RNU44 housekeeping snoRNA and expressed as percentage of ΔΔCt values calculated using the comparative cross threshold
method. miR-125b-5p expression level in cells cultured in absence of growth factors and exposed to DMSO was set as an internal reference.
(d) CCK-8 assay was performed 2 days after transfection of INA-6 and NCI-H929 cells with miR-125b-5p or miR-NC. IL-6 (2,5 ng/ml) or IGF-1
(100 ng/ml) or HGF (150 ng/ml) were added to complete culture medium. (e) 7-AAD ﬂow cytometry assay of INA-6 and NCI-H929 cells cultured
in the presence or absence of HS-5/GFP+ stromal cell line. The assay was performed 48 h after transfection of MM cells with miR-125b-5p
mimics or miR-NC. To discriminate between MM cells and HS-5 stromal cells, GFP negative cells were gated. (f) Flow cytometry analysis of
IL6-R/CD126 expression on cell surface of INA-6 cells after transfection with miR-125b-5p or miR-NC (48-h time point). (g) Western blot analysis
of total STAT3 (tSTAT3) and phosphorylated STAT3 (pSTAT3) in lysates from INA-6 cells transfected with miR-125b-5p or miR-NC (48-h time
point). GAPDH was used as protein loading control.
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chromosome 11 and hsa-miR-125b-2 on chromosome 21), coding
for the same mature sequences (miR-125b-5p and miR-125b-3p).45
miR-125b has a crucial role in a variety of cellular processes and
diseases.46 It is commonly dysregulated in cancer,46 but its
function diverges in different malignancies, with dependence on
the molecular contexts. However, its role in MM is still largely
undisclosed.46–48
We here provide the evidence that miR-125b acts as a tumor
suppressor in MM by targeting IRF4 and BLIMP-1 mRNAs, and
importantly we show that NLE-formulated synthetic miR-125b-5p
Figure 7. miR-125b-5p mimics antagonize MM tumor growth in vivo. In vivo growth of luciferase gene-marked NCI-H929 xenografts intra-
tumorally treated with miR-125b-5p mimics or scr controls. Palpable subcutaneous tumor xenografts were treated with 20 μg of NLE-
formulated oligos. Intra-tumor injections were administered every other day, for a total of six injections (indicated by arrows). (a) BLI-based
measurement of tumor volumes (three mice for each group) was made at 25 days from treatment. (b) Tumors were also measured with an
electronic caliper every other day (ﬁve mice for each group). Averaged tumor volume of each group ± s.d. is shown. P-values were obtained
using two-tailed t-test. (c) Survival curves (Kaplan–Meier) of intra-tumorally treated mice show prolongation of survival in miR-125b-5p-treated
NCI-H929 xenografts compared with controls (log-rank test, Po0.05). Survival was evaluated from the ﬁrst day of treatment until death or
sacriﬁce. Percentage of mice alive is shown. (d) In vivo tumor growth of NCI-H929 xenografts i.p. treated with NLE-formulated miR-125b-5p
or miR-NC. I.p. injections were administered twice weekly, for a total of four injections (indicated by arrows). Tumors were measured with an
electronic caliper every other day (ﬁve mice for each group). Averaged tumor volume of each group ± s.d. is shown. P-values were obtained
using two-tailed t-test. (e) Survival curves (Kaplan–Meier) of i.p.-treated mice show prolongation of survival in miR-125b-5p–treated NCI-H929
xenografts compared with controls (log-rank test, Po0.05). Survival was evaluated from the ﬁrst day of treatment until death or sacriﬁce.
Percentage of mice alive is shown. (f) qRT-PCR of miR-125b-5p expression in lysates from retrieved NCI-H929 xenografts intra-tumorally
treated with miR-125b-5p or miR-NC. The results shown are average miRNA expression levels after normalization with RNU44 and ΔΔCt
calculations. Data represent the average ± s.d. of three independent experiments. (g) Western blot analysis of BLIMP-1 and IRF4 in lysates from
a representative retrieved NCI-H929 xenograft intra-tumorally treated with miR-125b-5p or miR-NC. GAPDH was used as protein loading
control. (h) Western blot analysis of CASP10, cFLIP and c-Myc in lysates from a representative retrieved NCI-H929 xenograft intra-tumorally
treated with miR-125b-5p or miR-NC. GAPDH was used as a protein loading control.
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mimics induce anti-tumor activity in vivo. Speciﬁcally, we
demonstrate that both lentivirus-based constitutive expression
of miR-125b-1/-2 genes and transient enforced expression of
synthetic miR-125b-5p mimics inhibit the growth and survival of
MM cell lines. Moreover, viability of ppMM cells, but not of PBMCs
from healthy donors, was affected by transfection with miR-125b-
5p mimics, suggesting a favorable therapeutic activity. In our
study, baseline expression of miR-125b-5p does not correlate with
in vitro sensitivity of MM cells to synthetic mimics; consistent with
our ﬁndings, increasing evidence demonstrate that cancer cells
with normal miRNA expression are indeed susceptible to miRNA
treatment.35 Importantly, the anti-MM activity of miR-125b-5p
mimics was not affected by either exogenous growth promoting/
pro-survival stimuli including IL-6, IGF-1 or HGF, or by adherence
of MM cell lines to BM stromal cells (BMSCs). This is a crucial point
taking into account that the close and dynamic interplay between
MM cells and BMSCs leads to activation of signal transduction
pathways which promote cell-cycle progression and protection
from apoptosis.3 Furthermore, a c-Myc-mediated downregulation
of miR-125b by exposure of MM cells to different growth factors
was observed.
To date, a variety of oncogenic pathways have been identiﬁed
as directly regulated by miR-125b.46,47 Here, we demonstrate a
functional link between this miRNA and the oncogenic IRF4
signaling in MM. IRF4 is a validated target of miR-125b-5p37,49 and
the relevance of this interaction is well established in both
myeloid- and B-cell leukemias, wherein IRF4 acts as a tumor
suppressor and miR-125b as a tumor promoter.50 We found that
IRF4 expression was downregulated on transfection of MM cells
with miR-125b-5p mimics. Among the MM cell lines studied, only
miR-125b-5p-resistant RPMI-8226/Dox40 cells did not express
detectable levels of IRF4. Importantly, overexpression of IRF4 was
able to rescue SK-MM-1 cells from the growth-inhibitory activity of
miR-125b-5p. Altogether, these data indicate that IRF4 mediates
the anti-MM activity of miR-125b-5p mimics in vitro, underlying a
novel and divergent role of miR-125b-5p/IRF4 axis in MM as
compared with other hematological malignancies.
miRNAs function as master regulators of the genome by
modulating the expression of tens to hundreds genes, often
belonging to the same pathway.35 This mechanism of action
provides advantage to the therapeutic use of miRNAs, since it is
consistent with the current vision of cancer as a pathway
disease.35 Interestingly, the IRF4-downstream effector BLIMP-1 is
also regulated by miR-125b-5p,37 and we demonstrated that,
similar to IRF4 but to a lesser extent, it also mediates the growth-
inhibitory activity of miR-125b-5p. Moreover, we analyzed
perturbations occurring in other relevant effectors of IRF4
signaling, including c-Myc, casp-10 and cFlip. c-Myc has a
prominent role in the pathogenesis of MM, wherein it represents
an attractive therapeutic target.7,38,43 Importantly, ectopic expres-
sion of miR-125b-5p signiﬁcantly decreased c-Myc protein in MM
cells which was rescued by co-transfection with the coding region
of IRF4, indicating that IRF4 mediates miR-125b-5p-triggered
downregulation of c-Myc. Recently, it has been demonstrated that
MM cells further require the IRF4-downstream effectors casp-10
and cFlip for their survival: indeed, the heterodimeric protease
composed of casp-10 and cFLIP proteins has a balancing role
among the pro-survival and pro-death effects of autophagy.10
Consistent with these notions, we found that both casp-10 and
cFlip undergo signiﬁcant downregulation on miR-125b-5p ectopic
expression in MM cells, along with increased autophagic ﬂux.
Nonetheless, the role of autophagy as a response to miR-125b-5p
overexpression points to further investigation, taking into account
that our present data indeed suggest a protective effect at least in
SK-MM-1 cells. Even though in silico search for target prediction
indicated both casp-10 and cFlip as bona ﬁde direct targets for
miR-125b-5p, we failed to validate this interaction. However,
miR-125b-5p-induced downregulation of casp-10 and cFlip was
abrogated by ectopic IRF4 expression, indicating that miR-125b-
5p-mediated downregulation of these two survival factors
depends on IRF4 targeting.
Finally, we demonstrated the in vivo anti-tumor activity of NLE-
formulated miR-125b-5p mimics against human MM xenografts in
SCID/NOD mice. To our knowledge, this is the ﬁrst evidence of a
successful in vivo treatment with miR-125b-5p mimics in a murine
xenograft model of human MM, which indeed has important
potential towards clinical applications. We showed that both intra-
tumor and i.p. injection of NLE-formulated miR-125b-5p mimics
resulted in signiﬁcant tumor-growth inhibition and prolonged
survival. Moreover, in tumors retrieved from animals treated with
miR-125b-5p mimics, a downregulation of its direct targets IRF4
and BLIMP-1, along with a reduction in expression of c-Myc, casp-
10 and cFlip proteins, was observed. These ﬁndings suggest that
the in vivo anti-MM activity of miR-125b-5p mimics is related to
the impairment of IRF4 signaling within MM xenografts. Further
in vivo evaluation in preclinical models recapitulating the huBMM,
such as the SCID-synth-hu,51 will strengthen the translational
value of miR-125b-5p mimics.
We think that our study provides important proof-of-concept
ﬁndings for the basic strategy of miRNA therapeutics. In fact, we
found that the miR-125b-5p/IRF4 axis has a highly disease-speciﬁc
functional role in MM, which runs in opposite directions as
compared with other hematological malignancies. These ﬁndings
support the peculiarity of MM BM microenvironment disease
scenario, which opens highly speciﬁc therapeutic avenues.
An additional important point is that miR-125b-5p strongly
inhibits both IRF4 and BLIMP-1, offering a pathway-directed
therapeutic tool, which is still undruggable by alternative
approaches. In conclusion, our investigation provides evidence
that miR-125b has tumor-suppressor activity in MM and that
enforced expression of synthetic miR-125b-5p mimics induces
signiﬁcant anti-MM activity in vitro and in vivo by IRF4 targeting.
Taken together, these results provide the rational framework for
development of miR-125b-5p-based therapies in MM.
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